Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT04362839	TitleRegorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer	Fase Fase 1	Date Added 2020-04-27	Ubicación California, United States	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Ipilimumab, Nivolumab, Regorafenib, Opdivo, Stivarga, Yervoy	Etiquetas MSS/ MMRp
NCT ID NCT04110093	TitleRegorafenib más inhibidor de PD-1 en pacientes con cáncer colorrectal	Fase Fase 1/Fase 2	Date Added 2019-10-01	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Regorafenib e inhibidor de PD-1	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06006923	TitleRegorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer	Fase Fase 2	Date Added 2023-08-23	Ubicación California, United States Florida, United States Illinois, United States Pennsylvania, United States Washington, United States	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Pembrolizumab, Regorafenib, Keytruda, Stivarga	Etiquetas MSI-H/ MMRd
NCT ID NCT06456515	TitleRegorafenib and Sintilimab in Combination With Electroacupuncture in MSS CRC	Fase No aplicable	Date Added 2024-06-13	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSS/ MMRp
NCT ID NCT03657641	TitleRegorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer	Fase Fase 1	Date Added 2018-09-05	Ubicación California, United States Florida, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas Pembrolizumab, Regorafenib, Keytruda, Stivarga	Etiquetas MSS/ MMRp
NCT ID NCT04626635	TitleREGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors	Fase Phase 1, Phase 2	Date Added 2020-11-12	Ubicación California, United States Florida, United States Illinois, United States Iowa, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Wisconsin, United States Francia Israel Países Bajos Polonia España Turkey	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas cemiplimab, REGN7075	Etiquetas MSS/ MMRp
NCT ID NCT03388632	TitleInterleucina-15 recombinante en combinación con los inhibidores de puntos de control nivolumab e ipilimumab en pacientes con cáncer refractario	Fase Fase 1	Date Added 2018-01-03	Ubicación Maryland, United States	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas Ipilimumab, Nivolumab, rhIL-15, Opdivo, Yervoy	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05785325	TitleRC48-ADC combinado con bevacizumab en cáncer colorrectal avanzado HER2-positivo	Fase Fase 2	Date Added 2023-03-27	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas RC48-ADC más Bevacizumab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05292417	TitleRadiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC	Fase Fase 2	Date Added 2022-03-23	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Fruquintinib, GM-CSF, Sintilimab	Etiquetas MSS/ MMRp
NCT ID NCT04050709	TitleQUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers	Fase Fase 1	Date Added 2019-08-08	Ubicación California, United States	Prior IO Allowed No	CRC-directed No	Status Activo, no recluta	Drogas PD-L1 t-haNK	Etiquetas MSS/ MMRp

Showing 71 to 80 of 299 entries